Innovative Approaches to Parkinson's Treatment: SER-252 Unveiled
Serina Therapeutics Takes Center Stage at Upcoming Investor Webinar
Serina Therapeutics, Inc. (NYSE American: SER), a leading clinical-stage biotechnology company focused on innovative solutions for neurological disorders, is gearing up for an engaging presentation at an upcoming FORCE Family Office investor webinar. The session, titled "New Drug Optimization Platform to Transform Parkinson’s Care," will be led by Chief Executive Officer Steve Ledger on June 26, 2025. The event promises to shed light on pivotal advancements in Parkinson’s disease treatment.
Understanding Parkinson’s Disease: A Global Crisis
Parkinson’s disease is a neurological condition that affects millions globally, impairing their motor functions and diminishing their overall quality of life. In his presentation, Mr. Ledger aims to articulate the profound impact of advanced Parkinson’s on individuals and families. He will delve into the current treatment options available, emphasizing their limitations. Many existing medications provide only temporary relief and are often marred by side effects, including tremors and stiffness, which can exacerbate the burden on patients.
Introducing SER-252: A Breakthrough in Treatment
At the heart of Serina’s innovation is SER-252, a promising drug candidate designed to provide continuous symptom relief for Parkinson’s patients. This proprietary polymer conjugate of apomorphine represents a significant leap forward, enabling continuous dopaminergic stimulation (CDS). This approach is anticipated to not only smooth out the effects of medication but also extend the duration of symptom control, enhancing patient convenience and quality of life.
POZ Platform™: Transforming Drug Development
Serina Therapeutics has developed the POZ Platform™, an advanced drug optimization system that seeks to improve therapeutic safety, efficacy, and patient tolerance. With a focus on multiple treatment modalities, including small molecules and antibody-based drug conjugates (ADCs), the POZ Platform™ is at the forefront of Serina’s research and development efforts. By leveraging this innovative technology, Serina aims to redefine how neurological conditions are treated and managed.
Expected Highlights from the Webinar
Hosted by FORCE Family Office’s CEO, Steve Saltzstein, this event will allow attendees to engage directly with Mr. Ledger during a live Q&A session. Participants can submit questions during the webinar, making it an interactive experience. This session is not just an opportunity for investors but also for anyone interested in learning more about advancements in Parkinson’s care.
Registration Details
Attendance for this enlightening webinar is complimentary, encouraging a wide audience to join in and gain insights. Interested individuals may register online to ensure their spot and become part of the conversation about future innovations in medical science, particularly concerning Parkinson’s disease.
About Serina Therapeutics
Serina Therapeutics is dedicated to developing a robust pipeline of drug candidates with the potential to transform treatment paradigms for neurological diseases and other medical conditions. Based in Huntsville, Alabama, and situated on the prestigious HudsonAlpha Institute of Biotechnology campus, Serina’s commitment to pioneering research reflects its ambition to improve the lives of patients suffering from complex disorders.
About FORCE Family Office
FORCE Family Office stands as the largest network connecting family offices, foundations, endowments, and accredited investors in the U.S. By facilitating introductions between investors and industries, FORCE fosters an environment ripe for co-investments, information sharing, and invaluable networking opportunities.
Frequently Asked Questions
What is SER-252?
SER-252 is a drug candidate developed by Serina Therapeutics, designed to deliver continuous relief for Parkinson’s symptoms through a unique polymer conjugate of apomorphine.
When is the webinar taking place?
The webinar will take place on June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.
Who will host the webinar?
The webinar will be hosted by Steve Saltzstein, CEO of FORCE Family Office.
How can I register for the webinar?
Participants can register for the complimentary webinar online to secure their spot.
What is the goal of Serina Therapeutics?
Serina Therapeutics aims to develop innovative therapies to improve the treatment and management of neurological diseases, leveraging its proprietary POZ Platform™ technology.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.